(1)
LUND, Sweden, Jan. 26, 2021 /PRNewswire/ BioInvent International AB ( BioInvent or the Company ) (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces the enrollment of the first patient in a Phase I/IIa, first-in-human study of BI-1808 as monotherapy and in combination with the anti-PD-1 therapy Keytruda (pembrolizumab) for the treatment of solid tumors and cutaneous T-cell lymphoma (CTCL). The first patient in the Phase I/IIa study has been enrolled in Denmark.
BI-1808 is the lead development candidate from a panel of TNFR2-specific antibodies that BioInvent has generated from its proprietary n-CoDeR
BioInvent streamlines agreement on anti-FcyRllB antibody, BI-1206, ahead of Phase I/II data
LUND, Sweden, Jan. 11, 2021 /PRNewswire/ BioInvent International AB ( BioInvent or the Company ) (OMXS: BINV) today announces it has restructured a clinical development agreement with Cancer Research UK (CRUK), the world s leading cancer charity, for its unique anti-FcyRIIB antibody, BI-1206. In exchange for a one-time payment, the revised deal simplifies and reduces BioInvent s obligations to CRUK, which provides BioInvent with more flexibility to carry out development and partnering activities with BI-1206. It follows BioInvent s exclusive licensing agreement with CASI Pharmaceuticals for the development and commercialization of BI-1206 in mainland China, Taiwan, Hong Kong and Macau.
(1)
LUND, Sweden and STRASBOURG, France, Dec. 21, 2020 /PRNewswire/ BioInvent International AB ( BioInvent ) (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, and Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced they have received regulatory approval in Belgium for a clinical trial application (CTA) for a Phase l/lla study of the novel oncolytic vaccinia virus BT-001.
BT-001 is a best-in-class oncolytic
Vaccinia virus. It has been generated using Transgene s Invir.IO platform and its patented large-capacity VVcopTK-RR-